Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.
- Open access
The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.
Read the brief in JClub →